Aktienanalyse zu AptarGroup, Inc. (ATR)ATRAptarGroup, Inc.

AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets. It operates in the Basic Materials sector (PLASTICS PRODUCTS, NEC industry).

Aptargroup Inc is a good buy right now due to its current price of $124.51 being below the analyst price target range, with a forward P/E of 19.76 indicating attractive valuation. The RSI is at 71.48, suggesting it may be overbought, but the recent positive news about securing CE Mark for its device could drive future growth. The main risk is the recent decline below the 200-day moving average, which could indicate a bearish trend.

9 analysts cover ATR: 2 rate it Buy, 6 Hold and 1 Sell. The average price target is 145.33.